Posted by Michael Wonder on 21 Jan 2026
Truqap faces double barrier in Korea as NGS and drug reimbursement lag
20 January 2026 - As demand for next generation sequencing screening rises, a new drug for metastatic breast cancer faces access barriers in both diagnosis and treatment.
Truqap (capivasertib), the first AKT inhibitor therapy, was approved in Korea nearly two years ago but is not yet reimbursed. Although genetic testing is required, access to next generation sequencing remains limited and unreimbursed.
